Skip to main content

Published locations for Oral IL-23 receptor antagonist for psoriasis promising: Phase 2b study

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Oral IL-23 receptor antagonist for psoriasis promising: Phase 2b study

User login

  • Reset your password
  • /content/oral-il-23-receptor-antagonist-psoriasis-promising-phase-2b-study
  • /clinicianreviews/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase
  • /edermatologynews/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase
  • /familypracticenews/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase
  • /internalmedicinenews/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising
  • /rheumatologynews/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase
  • /rheumatology/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase-2b
  • /internalmedicine/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase
  • /dermatology/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase-2b
  • /familymedicine/article/264061/psoriasis/oral-il-23-receptor-antagonist-psoriasis-promising-phase-2b